(Q33394736)

26 July 2017

title

A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma (English)

1 reference

26 July 2017

1 reference

Michael P Brown

8

0 references

author name string

John M Kirkwood

1

1 reference

26 July 2017

Rene Gonzalez

2

1 reference

26 July 2017

Douglas Reintgen

3

1 reference

26 July 2017

Philip R Clingan

4

1 reference

26 July 2017

Robert R McWilliams

5

1 reference

26 July 2017

Dinesh P de Alwis

6

1 reference

26 July 2017

Annamaria Zimmermann

7

1 reference

26 July 2017

Robert L Ilaria

9

1 reference

26 July 2017

Michael J Millward

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

31 March 2011

1 reference

26 July 2017

1 reference

26 July 2017

volume

117

1 reference

26 July 2017

issue

20

1 reference

26 July 2017

page(s)

4732-4739

1 reference

Global cancer statistics, 2002

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

Metastatic melanoma: chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

Quantification of lean bodyweight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

The turnover rate of serum albumin in man as measured by I131-tagged albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26068

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.26068

1 reference

26 July 2017

1 reference